- The FDA removes the Clinical Hold on Juno Therapeutics' (NASDAQ:JUNO) Phase 2 clinical trial, ROCKET, assessing lead CAR-T candidate JCAR015 for the treatment of adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
- The agency recently stopped the study after two patients died after receiving the preconditioning regimen of cyclophosphamide + fludarabine. Henceforward, study participants will be preconditioned with cyclophosphamide only.
- Shares are up 28% after hours on robust volume.
- Competitor Kite Pharma (NASDAQ:KITE) is enjoying some buying as well. Shares are up 8% after hours on increased volume.
- Previously: Juno's mid-stage study of lead CAR-T candidate on clinical hold after two deaths; shares plummet 31% after hours (July 7)